This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

To learn more about the topics in this episode:
Top 10 most anticipated drug launches of 2024
BMS unwraps $14B deal for Karuna, adding a schizophrenia drug awaiting FDA OK
Bristol Myers Squibb has targeted launch plan for ‘multi-billion-dollar opportunity’ in Karuna schizophrenia drug
Meet Madrigal Pharmaceuticals, which wants to be your liver's No. 1 fan

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercepharma.com/special-reports/top-10-most-anticipated-drug-launches-2024" data-cke-saved-href="https://www.fiercepharma.com/special-reports/top-10-most-anticipated-drug-launches-2024">Top 10 most anticipated drug launches of 2024</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/bms-unwraps-14b-deal-karuna-adding-schizophrenia-drug-awaiting-fda-ok" data-cke-saved-href="https://www.fiercebiotech.com/biotech/bms-unwraps-14b-deal-karuna-adding-schizophrenia-drug-awaiting-fda-ok">BMS unwraps $14B deal for Karuna, adding a schizophrenia drug awaiting FDA OK</a></li>
<li><a href="https://www.fiercepharma.com/marketing/bristol-myers-squibb-has-targeted-launch-plan-multi-billion-dollar-opportunity-karuna" data-cke-saved-href="https://www.fiercepharma.com/marketing/bristol-myers-squibb-has-targeted-launch-plan-multi-billion-dollar-opportunity-karuna">Bristol Myers Squibb has targeted launch plan for ‘multi-billion-dollar opportunity’ in Karuna schizophrenia drug</a></li>
<li><a href="https://www.fiercepharma.com/marketing/meet-madrigal-who-wants-be-your-livers-number-one-fan" data-cke-saved-href="https://www.fiercepharma.com/marketing/meet-madrigal-who-wants-be-your-livers-number-one-fan">Meet Madrigal Pharmaceuticals, which wants to be your liver's No. 1 fan</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement